Her-2低表达乳腺癌临床病理特征及生存状况分析  

Clinicopathological Features and Survival Conditions of Breast Cancer with Her-2 Low-expression

作　　者：段帅 地力木拉提·艾斯木吐拉[1] 王海燕[1] 李慧芳[1] 汪丹丹 卡吾力·居买 郭晨明 DUAN Shuai;Dilimulati·AISIMUTULA;WANG Haiyan(Department of Breast Surgery,The First Affiliated Hospital of Xinjiang Medical University,Xinjiang 830054,China)

机构地区：[1]新疆医科大学第一附属医院乳腺外科,乌鲁木齐830054

出　　处：《医学研究杂志》2024年第8期115-120,共6页Journal of Medical Research

基　　金：新疆维吾尔自治区自然科学基金资助项目(面上项目)(2022D01A140);省部共建中亚高发病成因与防治国家重点实验室项目(SKL-HIDCA-2021-41)。

摘　　要：目的分析人表皮生长因子受体-2(human epidermal growth factor receptor-2,Her-2)低表达与Her-2阴性乳腺癌的临床病理特征及生存状况。方法回顾性收集2013年4月~2022年11月就诊于新疆医科大学第一附属医院的327例定义为Her-2阴性或低表达乳腺癌患者的临床病理和预后生存资料,依据Her-2状态分为Her-2低表达组(n=217)和Her-2阴性组(n=110)。比较两组患者的临床病理特征、治疗后复发转移情况、病死率、总生存期和无疾病进展生存期等,并依据激素受体(hormone receptor,HR)状态分为HR+和HR-队列,比较两种队列下Her-2阴性或低表达乳腺癌患者的无疾病进展生存期。结果Her-2低表达乳腺癌临床中占比高,多合并雌激素受体(estrogen receptor,ER)阳性,表现为Luminal型,病理预后分期多为Ⅰ期,且ki-67低表达;而Her-2阴性乳腺癌多合并ER阴性,表现为三阴性型,病理预后分期多为Ⅲ期,ki-67高表达,并在治疗后出现更多的脑转移和(或)其他脏器转移,差异有统计学意义(P<0.05)。但两组患者在病死率、总生存期、组间及两种队列间无疾病进展生存期方面比较,差异无统计学意义(P>0.05)。结论Her-2低表达与Her-2阴性乳腺癌之间存在肿瘤异质性,Her-2低表达乳腺癌具有ER阳性率高,ki-67低表达,病理预后分期较早等优势,且治疗后脑转移和(或)其他脏器转移率较低,但尚未转换为显著的生存获益。Objective To analyze the clinicopathological features and survival conditions of human epidermal growth factor receptor-2(Her-2)negative and low-expression breast cancer.Methods Aretrospective analysis was performed for the clinicopathological and prognostic survival data of 327 patients of Her-2 negative or low-expression breast cancer who visited the First Affiliated Hospital of Xinjiang Medical University from April 2013 to November 2022,and were divided into the Her-2 low-expression group(n=217)and the Her-2 negative group(n=110).The clinicopathological features,and prognostic survival indicators such as recurrence and metastasis after treatment,mortality,overall survival,and progression-free survival of the two groups were compared.According to the hormone receptor(HR)status,the patients were divided into HR+and HR-cohorts,and the progression-free survival of patients with Her-2 negative or low-expression breast cancer in the two cohorts was compared.Results Breast cancer with Her-2 low-expression accounted for a high proportion in the clinic,most of them were estrogen receptor(ER)-positive manifested as Luminal type,the pathological prognosis stage was mostly stageⅠ,and ki-67 was low expression.However,Her-2 negative breast cancer was often combined with ER-negative manifestations as triple-negative type,the pathological prognosis stage was mostly stage Ⅲ,and ki-67 was highly expression,and more brain metastases and/or other organ metastases appeared after treatment,all the differences were statistically significant(P<0.05).However,There were no statistical differences in mortality,overall survival,and progression-free survival between groups and the two cohorts(P>0.05).Conclusion There is tumor heterogeneity between Her-2 negative and low-expression breast cancer,Her-2 low-expression breast cancer has the advantages of high ER positive rate,low ki-67 expression,and early stage of pathological prognosis and stage,and the metastasis rate of the brain metastases and/or other organs is relatively low after

关 键 词：乳腺癌 人表皮生长因子受体-2 低表达 特征 生存状况 

分 类 号：R737.9[医药卫生—肿瘤]